Cases That Test Your Skills

A 95-year-old man with treatment-resistant depression

Author and Disclosure Information

 

References

Neurocognitive effects

Reports on the effects of ECT on neurocognitive functioning have varied. In some studies, performance improved or did not change in severely depressed older patients who received ECT.18,19 In older people who receive ECT, MMSE scores often return to baseline by the end of treatment.20 There often is only mild transient cognitive impairment in patients with late-life depression who receive ECT. Areas of concern include attention span, orientation, and speed of mental processing.20 Physicians should conduct cognitive tests before, during, and after ECT sessions to monitor their patient’s mental status.20

Cognitive stability can be maintained by administering ECT twice a week; applying right-sided, unilateral electrode placement; and using short, ultra-brief stimulus pulse width parameters.21 Cognitive impairment induced by ECT is not associated with age in geriatric patients with depression.22 Older adults who experienced longer postictal reorientation time periods have better outcomes than others who reach orientation faster; their intellectual impairment returned to baseline.20 Falling is another complication associated with ECT. A longitudinal cohort study found the incident of falls among patients receiving ECT was 13%.22 Risk factors for falls during a course of ECT include the number of treatments and the presence of coexisting Parkinson’s disease.23

OUTCOME Improvement

Mr. R receives 8 sessions of right-sided, unilateral ECT with an individualized dosage titration method. Treatments are completed with a stimulus intensity at 6 times seizure threshold, with an ultra-brief pulse width at 0.3 milliseconds. Mr. R’s mood and affect begin to improve after 3 ECT sessions. His MMSE score increases to 28/30 (Figure). His clinical improvement is progressively sustained; he develops an increasingly jovial attitude and experiences less anxiety. Mr. R’s confidence, appetite, and sleep also improve. There are no complications with treatment, and Mr. R has no complaints. After 8 ECT sessions, Mr. R has no affective symptoms and does not experience any cognitive impairment.

The authors’ observations

Depression among older people is a growing public health concern. It is a leading cause of disability, and often leads to nursing home placement.24 ECT is a safe, effective treatment for late-life depression, but is underutilized in patients age >75 because of concerns for cognitive impairment.6 However, there is evidence that response rates to ECT are higher in patients ages 45 to 85, compared with young individuals ages 18 to 45.25 ECT is a viable intervention for older depressed patients, particularly for those who do not tolerate or fail to respond to pharmacotherapy. Many of these patients are at risk for drug-induced toxicities or interactions or suicide.1

Bottom Line

Electroconvulsive therapy (ECT) is a safe, effective treatment for depression. Although there are only a few case reports of patients in their 90s who have received ECT, evidence supports ECT as an appropriate intervention for geriatric patients with depression.

Related Resources

  • Salzman C, Wong E, Wright BC. Drug and ECT treatment of depression in the elderly, 1996-2001: a literature review. 2002;52(3):265-284.
  • Blumberger DM, Hsu JH, Daskalakis ZJ. A review of brain stimulation treatments for late-life depression. 2015;2(4):413-421.

Drug Brand Names

Buspirone Buspar
Escitalopram Lexapro
Mirtazapine Remeron
Quetiapine Seroquel
Risperidone Risperdal

Pages

Recommended Reading

A concise guide to monoamine oxidase inhibitors
MDedge Psychiatry
Dietary restrictions with MAOIs
MDedge Psychiatry
‘Tea with Freud’: Engaging, authentic, but nonanalytic
MDedge Psychiatry
Antidepressant therapy is too often tardy
MDedge Psychiatry
Self-harm on rise in U.S. among girls aged 10-14
MDedge Psychiatry
Helping patients process sexual harassment
MDedge Psychiatry
Physician health programs: ‘Diagnosing for dollars’?
MDedge Psychiatry
Poststroke depression raises risk of cerebrovascular death 35-fold
MDedge Psychiatry
Inside the ‘mad rush’ for ketamine treatment
MDedge Psychiatry
More evidence backs adjunctive intranasal esketamine for refractory depression
MDedge Psychiatry